Sphera Funds Management LTD. holds a diversified book of 92 stocks worth $581.5M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened AstraZeneca PLC and trimmed Biogen Inc. Their largest long position is Mineralys Therapeutics Inc at 6% of the equity book. They also disclosed $25.5M in put options (a bearish bet) and $22.7M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1496201/holdings"
Use Arkolith to show SPHERA FUNDS MANAGEMENT LTD.'s latest holdings, largest changes, and filing provenance.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
94% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Mineralys Therapeutics Inc COM | $36.3M | 1.34M | 6.2% | ▲+198% Added · +891K sh | |
| 2 | Teva Pharmaceutical Inds Ltd SPONSORED ADS | $34.2M | 1.14M | 5.9% | ▲+1.2% Added · +13K sh | |
| 3 | Tower Semiconductor Ltd SHS NEW | $25.6M | 145.7K | 4.4% | ▲+19% Added · +23K sh | |
| 4 | Nova Ltd COM | $23.2M | 53.4K | 4.0% | ▲+12% Added · +6K sh | |
| 5 | Bridgebio Pharma Inc COM | $18.2M | 245.2K | 3.1% | ▲+128% Added · +138K sh | |
| 6 | Biogen Inc COM | $17.0M | 92.5K | 2.9% | ▼−2.3% Reduced · −2K sh | |
| 7 | Ultragenyx Pharmaceutical In COM | $17.0M | 809.3K | 2.9% | ▲+169% Added · +509K sh | |
| 8 | Syndax Pharmaceuticals Inc COM | $16.9M | 724.6K | 2.9% | ▼−5.0% Reduced · −38K sh | |
| 9 | Cogent Biosciences Inc COM | $16.0M | 416.3K | 2.8% | ▲+10.0% Added · +38K sh | |
| 10 | Sanofi Sa SPONSORED ADR | $13.0M | 269.5K | 2.2% | ▲+13% Added · +30K sh | |
| 11 | AstraZeneca PLC ORD | $12.3M | 62.5K | 2.1% | ▲New New position | |
| 12 | Amicus Therapeutic COM | $8.7M | 603.4K | 1.5% | ▼−8.3% Reduced · −55K sh | |
| 13 | Cellebrite Di Ltd ORDINARY SHARES | $8.7M | 631.5K | 1.5% | ▲New New position | |
| 14 | Apellis Pharmaceuticals Inc COM | $8.6M | 214.9K | 1.5% | ▼−14% Reduced · −36K sh | |
| 15 | Palo Alto Networks Inc COM | $8.5M | 52.8K | 1.5% | ▲New New position | |
| 16 | Eli Lilly & Co COM | $8.3M | 9.0K | 1.4% | —Held | |
| 17 | Biocryst Pharmaceuticals Inc COM | $8.2M | 866.5K | 1.4% | ▲+3.4% Added · +29K sh | |
| 18 | Camtek Ltd ORD | $8.0M | 53.0K | 1.4% | ▲+34% Added · +14K sh | |
| 19 | Biomarin Pharmaceutical Inc COM | $7.9M | 139.9K | 1.4% | ▼−4.8% Reduced · −7K sh | |
| 20 | Celldex Therapeutics Inc New COM NEW | $7.7M | 243.6K | 1.3% | ▲+1.6% Added · +4K sh | |
| 21 | Ormat Technologies Inc COM | $7.6M | 68.3K | 1.3% | ▲New New position | |
| 22 | Xenon Pharmaceuticals Inc COM | $7.4M | 127.0K | 1.3% | ▲New New position | |
| 23 | Soleno Therapeutics Inc COM | $7.2M | 216.3K | 1.2% | ▲+59% Added · +80K sh | |
| 24 | Tango Therapeutics Inc COM | $7.2M | 343.6K | 1.2% | ▼−37% Reduced · −201K sh | |
| 25 | Johnson & Johnson COM | $7.0M | 28.8K | 1.2% | ▼−20% Reduced · −7K sh | |
| 26 | Solaredge Technologies Inc NOTE 2.250% 7/0 | $6.9M | 4.00M | 1.2% | —Held | |
| 27 | Immatics N.V SHS | $6.8M | 696.1K | 1.2% | ▼−19% Reduced · −165K sh | |
| 28 | Trevi Therapeutics Inc COM | $6.8M | 574.0K | 1.2% | ▼−4.1% Reduced · −25K sh | |
| 29 | Oric Pharmaceuticals Inc COM | $6.8M | 537.6K | 1.2% | ▼−46% Reduced · −467K sh | |
| 30 | Maze Therapeutics Inc COM | $6.8M | 227.3K | 1.2% | ▲+216% Added · +156K sh | |
| 31 | GSK PLC SPONSORED ADR | $6.7M | 122.0K | 1.2% | —Held | |
| 32 | Amazon Com Inc COM | $6.7M | 31.9K | 1.1% | ▲New New position | |
| 33 | Abbvie Inc COM | $6.6M | 30.3K | 1.1% | ▲+20% Added · +5K sh | |
| 34 | Applied Optoelectronics Inc COM | $6.2M | 73.4K | 1.1% | ▲New New position | |
| 35 | Enliven Therapeutics Inc COM | $6.0M | 153.3K | 1.0% | ▼−32% Reduced · −74K sh | |
| 36 | Merck & Co Inc COM | $5.8M | 48.6K | 1.0% | —Held | |
| 37 | Vor Biopharma Inc COM NEW | $5.7M | 321.9K | 1.0% | ▼−22% Reduced · −89K sh | |
| 38 | Acadia Pharmaceuticals Inc COM | $5.7M | 256.2K | 1.0% | ▲+21% Added · +44K sh | |
| 39 | Novartis AG SPONSORED ADR | $5.7M | 37.0K | 1.0% | —Held | |
| 40 | Eledon Pharmaceuticals Inc COM | $5.5M | 1.77M | 0.9% | ▼−17% Reduced · −360K sh | |
| 41 | Enphase Energy Inc COM | $5.4M | 142.4K | 0.9% | ▼−24% Reduced · −44K sh | |
| 42 | Revolution Medicines Inc COM | $5.4M | 55.1K | 0.9% | ▲+5.0% Added · +3K sh | |
| 43 | Pfizer Inc COM | $5.2M | 186.0K | 0.9% | ▲+116% Added · +100K sh | |
| 44 | Biohaven Ltd COM | $5.0M | 594.0K | 0.9% | ▲New New position | |
| 45 | Forte Biosciences Inc COM NEW | $4.8M | 185.0K | 0.8% | ▼−0.5% Reduced · −885 sh | |
| 46 | Cybin Inc COM NEW | $4.7M | 987.1K | 0.8% | ▲+20% Added · +162K sh | |
| 47 | Madrigal Pharmaceuticals Inc COM | $4.7M | 9.0K | 0.8% | ▲+174% Added · +6K sh | |
| 48 | Scholar Rock Hldg Corp COM | $4.6M | 94.3K | 0.8% | ▼−40% Reduced · −64K sh | |
| 49 | Novo-Nordisk A S ADR | $4.4M | 120.7K | 0.8% | ▲+4.3% Added · +5K sh | |
| 50 | Mediwound Ltd SHS NEW | $4.4M | 273.2K | 0.8% | ▲+19% Added · +43K sh |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | SS SPDR S&P BIOTECH ETFXBI | $25.5M | 200K |
| CALL · bullish | CYTOKINETICS INCCYTK | $17.1M | 259K |
| CALL · bullish | ISHARES 20+ YEAR TREASURY BDTLT | $4.1M | 47K |
| CALL · bullish | OLEMA PHARMACEUTICALS INCOLMA | $1.5M | 100K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.